Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Open for collaboration: an academic platform for drug discovery and development at SciLifeLab
Uppsala University, Science for Life Laboratory, SciLifeLab. Drug Discovery & Development Platform & Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neuro-Oncology. Uppsala University, Science for Life Laboratory, SciLifeLab.
2016 (English)In: Drug Discovery Today, ISSN 1359-6446, E-ISSN 1878-5832, Vol. 21, no 10, p. 1690-1698Article, review/survey (Refereed) Published
Abstract [en]

The Science for Life Laboratory Drug Discovery and Development (SciLifeLab DDD) platform reaches out to Swedish academia with an industry-standard infrastructure for academic drug discovery, supported by earmarked funds from the Swedish government. In this review, we describe the build-up and operation of the platform, and reflect on our first two years of operation, with the ambition to share learnings and best practice with academic drug discovery centers globally. We also discuss how the Swedish Teacher Exemption Law, an internationally unique aspect of the innovation system, has shaped the operation. Furthermore, we address how this investment in infrastructure and expertise can be utilized to facilitate international collaboration between academia and industry in the best interest of those ultimately benefiting the most from translational pharmaceutical research - the patients.

Place, publisher, year, edition, pages
2016. Vol. 21, no 10, p. 1690-1698
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-311790DOI: 10.1016/j.drudis.2016.06.026ISI: 000386401000014PubMedID: 27373760OAI: oai:DiVA.org:uu-311790DiVA, id: diva2:1061442
Available from: 2017-01-02 Created: 2017-01-02 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

fulltext(723 kB)157 downloads
File information
File name FULLTEXT01.pdfFile size 723 kBChecksum SHA-512
1e8971d6703dde1ee60cae4b4db321e75a37d7007cdc5b7be9ccf5a42e3f357afc5aa4e7d8565590e2e66a1d587e924805b423ef86dde65b3b4ea7d54d1e7b35
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Arvidsson, Per I.Sandberg, KristianForsberg-Nilsson, Karin
By organisation
Science for Life Laboratory, SciLifeLabOrganic Pharmaceutical ChemistryNeuro-Oncology
In the same journal
Drug Discovery Today
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 157 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 610 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf